



## ABIVAX to participate in the upcoming RBC Capital Markets 2016 Healthcare Conference in New York, and in the Credit Suisse Healthcare Conference in London

Paris, France, February 11<sup>th</sup>, 2016 – ABIVAX (Euronext Paris: FR0012333284 – ABVX), an emerging leader in developing and commercializing anti-viral drugs and therapeutic vaccines for diseases like HIV/AIDS and chronic hepatitis B (CHB), today announced that its CEO, Prof. Hartmut Ehrlich, M.D., will participate in the RBC Capital Markets 2016 Healthcare Conference in New York on February 23<sup>rd</sup> and 24<sup>th</sup>, and in the Credit Suisse Healthcare Conference in London on March 1<sup>st</sup> and 2<sup>nd</sup>.

At the **RBC Capital Markets 2016 Healthcare conference**, Prof. Ehrlich is scheduled to participate in a fireside chat with RBCCM healthcare analyst Douglas Miehme at 8:30 AM (EST) on February 23rd. This conversation will be webcast, and will be available on ABIVAX's website. Additionally, Prof. Ehrlich and ABIVAX's CFO, Alain Chevallier, will conduct one-on-one meetings with interested investors over the course of the conference.

At the **Credit Suisse Healthcare conference in London**, Prof. Ehrlich and Mr. Chevallier will meet with investors in one-on-one meetings over the course of the conference.

**ABIVAX** ([www.abivax.com](http://www.abivax.com)) is an emerging global leader in the discovery, development and commercialization of anti-viral therapeutics and vaccines to treat some of the world's most life-threatening infectious diseases, including HIV/AIDS and chronic Hepatitis B. ABIVAX has 2 compounds in clinical stage research: ABX464 a novel first-in-class resistance-proof oral small molecule HIV/AIDS therapy; and, ABX203, a therapeutic vaccine that could cure chronic Hepatitis B. ABIVAX also is advancing additional anti-viral compounds and therapeutic vaccines that may enter the clinical stage in the coming 18 months. Follow us on Twitter @ABIVAX\_

### Contacts

#### Investor relations

Raquel Lizarraga  
[raquel.lizarraga@abivax.com](mailto:raquel.lizarraga@abivax.com)  
+33 1 53 83 09 63

#### Citigate Dewe Rogerson

Lucie Languier  
[abivax@citigate.fr](mailto:abivax@citigate.fr)  
+33 1 53 32 84 75

#### LifeSci Advisors

Chris Maggos  
[chris@lifesciadvisors.com](mailto:chris@lifesciadvisors.com)  
+41 79 367 6254

#### Press relations

**ALIZE RP**  
Caroline Carmagnol and Florence Portejoie  
[abivax@alizerp.com](mailto:abivax@alizerp.com)  
+33 6 64 18 99 59 / + 33 1 44 54 36 64